Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (4): 651-655.doi: 10.16352/j.issn.1001-6325.2022.04.019

• Mini Reviews • Previous Articles     Next Articles

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors

GAN Zi-ying1, TANG Hui2*   

  1. 1. School of Medical, Kunming University of Science and Technology; 2. Yunnan Digestive Endoscopy Clinical Medical Center, Kunming Key Laboratory of Tumor Molecular & Immune Prevention, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032,China
  • Received:2020-12-14 Revised:2021-04-06 Online:2022-04-05 Published:2022-04-01
  • Contact: *

Abstract: Oncolytic viruses are often used in combination with immune checkpoint inhibitors represented in two ways by programmed cell death 1/programmed cell death-Ligand 1 (PD-1/PD-L1). One is oncolytic virus combined with PD-1/PD-L1 inhibitors, which is modified by gene recombination and natural weak toxicity, and another one is oncolytic virus with gene recombination carrying PD-1/PD-L1 antibody gene.

Key words: PD-1/PD-L1, immune checkpoint inhibitor, oncolytic therapy

CLC Number: